首页> 美国卫生研究院文献>Cancers >Osteopontin as a Regulator of Colorectal Cancer Progression and Its Clinical Applications
【2h】

Osteopontin as a Regulator of Colorectal Cancer Progression and Its Clinical Applications

机译:Osteopontin作为结直肠癌进展的调节剂及其临床应用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The mortality of colorectal cancer is principally related to metastatic disease at the time of diagnosis or to the growth of initially undetectable micro-metastasis. Current therapeutic strategies are efficient in patients with locally advanced cancer, but are rarely able to cure patients with metastatic disease. Therapeutic failure is mainly associated with drug resistance and an aggressive phenotype. The identification of new biomarkers for micro-metastasis and tumor progression remains an unmet clinical need that should allow for improved patient stratification for optimal treatment and may lead to the identification of novel therapeutic targets. Osteopontin (OPN), a multifunctional protein, has emerged as a potentially valuable biomarker in several cancer types. This review principally describes the molecular mechanisms of OPN that are associated with colorectal cancer (CRC) progression and metastasis, as well as the use of OPN as a clinical biomarker. This review identifies a role for OPN as a biomarker ready for extended clinical application and discusses its use as a therapeutic target.
机译:结肠直肠癌的死亡率主要与诊断时的转移性疾病或最初未检测到的微转移的生长有关。目前的治疗策略在局部晚期癌症的患者中是有效的,但很少能够治愈转移性疾病的患者。治疗失败主要与耐药性和激进表型相关。用于微转移和肿瘤进展的新生物标志物的鉴定仍然是未接受的临床需求,允许改善患者分层以获得最佳治疗,并可能导致新的治疗靶标的鉴定。骨桥蛋白(OPN),多官能蛋白,在几种癌症类型中被出现为潜在有价值的生物标志物。本综述主要描述了与结肠直肠癌(CRC)进展和转移相关的OPN的分子机制,以及使用OPN作为临床生物标志物的使用。该审查标识了OPN作为BIOMarker的作用,准备扩展临床应用,并讨论其用作治疗目标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号